New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
11:16 EDTMNKD, GALT, CYTK, DLLR, APOLOptions with decreasing implied volatility: MNKD GALT CYTK DLLR APOL
News For MNKD;GALT;CYTK;DLLR;APOL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
16:10 EDTCYTKCytokinetics sees FY14 cash revenues $19M-$21M
Subscribe for More Information
16:09 EDTCYTKCytokinetics reports Q3 EPS (16c), consensus (24c)
Reports Q3 revenue $9.4M, consensus $7.38M.
12:22 EDTAPOLGrand Canyon jumps after announcing exploration of non-profit status
Subscribe for More Information
06:58 EDTAPOLRule would close fewer for-profit programs than previous draft, Politico says
Subscribe for More Information
October 27, 2014
10:43 EDTAPOLOptions with decreasing implied volatility
Subscribe for More Information
07:39 EDTCYTKCytokinetics provides development program update for omecamtiv mecarbil
Cytokinetics provided an update relating to omecamtiv mecarbil, the company's lead drug candidate from its cardiac muscle contractility program. The company announced that COSMIC-HF, or Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure, has enrolled over 275 patients towards the objective of 450 patients in the ongoing expansion phase of the trial. In addition, over 70 patients have completed the 20 weeks of dosing in the expansion phase of COSMIC-HF. Recently, the Data Monitoring Committee reviewed data from COSMIC-HF and recommended that the trial continue without any changes to the protocol. Patient enrollment in COSMIC-HF is expected to conclude by the end of 2014. The company also announced that CY 1211, a Phase I study comparing the tolerability and pharmacokinetics of omecamtiv mecarbil between Japanese and Caucasian healthy volunteers, is complete and indicates no clinically meaningful differences between the two groups studied. Data from CY 1211 are expected to inform plans for the development of omecamtiv mecarbil in Japan and the inclusion of Japan in potential global Phase III program activities.
October 24, 2014
10:29 EDTAPOLOptions with decreasing implied volatility
Subscribe for More Information
October 22, 2014
05:58 EDTMNKDStocks with implied volatility movement; MNKD SHPG
Subscribe for More Information
October 21, 2014
07:34 EDTAPOLApollo Education sees 1Q15 revenue $720M-$730M, consensus $763.70M
Subscribe for More Information
07:33 EDTAPOLApollo Education sees FY15 revenue $2.8B-$2.85B, consensus $2.80B
07:32 EDTAPOLApollo reports Q4 University of Phoenix New Degreed Enrollment down 5.9%
Subscribe for More Information
07:31 EDTAPOLApollo Education reports Q4 EPS from cont. ops. ex-items 34c, consensus 27c
Subscribe for More Information
October 20, 2014
07:37 EDTCYTKCytokinetics completes review results from BENEFIT-ALS regarding tirasemtiv
Cytokinetics provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful. In addition, following consultation with clinical and statistical experts, the company believes that data from BENEFIT-ALS support progression of tirasemtiv to a potential Phase III clinical trial in patients with amyotrophic lateral sclerosis (ALS). The company also announced that it has begun regulatory interactions with the U.S. Food and Drug Administration regarding results from BENEFIT-ALS and has received initial feedback from the FDA. The company believes that effects on SVC could be a Phase III clinical trial endpoint and could support registration of tirasemtiv as a potential treatment for patients with ALS. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Cytokinetics has received feedback from the FDA following initial communications regarding tirasemtiv and BENEFIT-ALS. The company believes that the FDA may be willing to consider a potential registration path for tirasemtiv relating to effects on SVC. The company expects to have additional interactions with the FDA and other regulatory authorities. In addition, the company has commenced Phase III readiness activities including designing a potential Phase III clinical trial in order to inform plans, timelines and costs associated with the further development of tirasemtiv.
06:52 EDTMNKDMannKind initiated with a Neutral at Goldman
Target $6.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use